系统性硬化症合并抗中性粒细胞胞质抗体相关性血管炎:独特的临床重叠及其对治疗与结局的重要影响
这项法国18中心回顾性研究纳入30例符合2013年ACR/EULAR系统性硬化症(SSc)分类标准及2022年ACR/EULAR抗中性粒细胞胞质抗体相关性血管炎(AAV)分类标准的重叠患者。AAV均为在SSc之后发生,以显微镜下多血管炎(90%)和MPO-ANCA阳性(93%)为主,肾脏受累常见(76%)。所有患者接受糖皮质激素联合环磷酰胺(50%)或利妥昔单抗(47%)治疗,未观察到硬皮病肾危象,SSc表现(包括ILD和皮肤受累)保持稳定。
要点
- SSc患者可重叠AAV,以显微镜下多血管炎和MPO-ANCA阳性为主。
- 重叠患者中纤维化型ILD和抗Scl70抗体常见。
- 标准血管炎治疗未加重SSc,未观察到硬皮病肾危象。
核心结论
- AAV可发生于SSc患者,尤其见于纤维化型ILD和抗Scl70抗体阳性者。
- 标准血管炎治疗似乎有效且不恶化SSc结局。
研究设计与样本
- 多中心回顾性研究,纳入法国18个中心符合2013年ACR/EULAR SSc分类标准和2022年ACR/EULAR AAV分类标准的患者,共30例,中位年龄51.5岁,女性占83%。
主要发现
- AAV均在SSc之后发生,27%为弥漫性皮肤型SSc,73%为局限皮肤型SSc。
- 抗Scl70抗体阳性者占50%,ILD占80%,以纤维化型非特异性间质性肺炎模式为主(54%)。
- AAV为显微镜下多血管炎者占90%,MPO-ANCA阳性者占93%。
- 肾脏受累占76%,中位血清肌酐170 μmol/L(IQR 120-361 μmol/L),蛋白尿(尿蛋白/肌酐比)为2 g/g肌酐(IQR 0.9-2.3 g/g肌酐)。
- 随访期间SSc表现(包括ILD和皮肤受累)保持稳定,未观察到硬皮病肾危象。
关键数值与推荐
- 所有患者接受糖皮质激素联合环磷酰胺(50%)或利妥昔单抗(47%)治疗。
临床怎么用
- 对SSc患者出现肾脏受累等血管炎表现时,应检测ANCA以识别重叠AAV。
- 确诊重叠AAV后可采用标准血管炎治疗方案,包括糖皮质激素联合环磷酰胺或利妥昔单抗。
局限性
- 回顾性研究设计,样本量较小(30例),可能限制结论的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disease characterized by autoantibody production, fibrosis, and vasculopathy. The coexistence of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) in SSc is rare and poorly characterized, with limited data on the impact of treatments, particularly high-dose glucocorticoids (GCs), on both conditions. This study aimed to describe the clinical phenotype, management, and outcomes of patients with overlapping SSc and AAV. METHODS: We conducted a multicenter retrospective study in 18 French centers, including patients who met the 2013 American College of Rheumatology (ACR)/EULAR criteria for SSc and the 2022 ACR/EULAR criteria for AAV. Clinical, biologic, and radiologic data were collected. RESULTS: We included 30 patients (median age 51.5 years, 83% female). SSc preceded AAV in all cases; 27% had diffuse cutaneous SSc, whereas 73% had limited cutaneous SSc. Anti-Scl70 antibodies were detected in 50%, and interstitial lung disease (ILD) was present in 80%, predominantly with a fibrosing nonspecific interstitial pneumonia pattern (54%). AAV was microscopic polyangiitis in 90%, with myeloperoxidase (MPO)-ANCA positivity in 93%. Renal involvement was common (76%), with a median serum creatinine level of 170 μmol/L (interquartile range [IQR] 120-361 μmol/L) and proteinuria (urine protein to creatinine ratio of 2 g/g creatinine [IQR 0.9-2.3 g/g creatinine]). All patients received GCs in combination with cyclophosphamide (50%) or rituximab (47%). No cases of scleroderma renal crisis were observed. SSc manifestations, including ILD and skin involvement, remained stable during follow-up. CONCLUSION: AAV, predominantly microscopic polyangiitis with MPO-ANCA, can occur in SSc, particularly in patients with fibrosing ILD and anti-Scl70. Standard vasculitis treatments appear to be effective and do not worsen outcomes in SSc.
引用
- Eshagh D, Quéméneur T, Karras A, et al. Antineutrophil Cytoplasmic Antibody-Associated Vasculitides in Systemic Sclerosis: A Unique Clinical Overlap With Significant Implications for Treatment and Outcomes. Arthritis Rheumatol. 2026. PMID: 41451470. doi:10.1002/art.70032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。